Lilly(US:LLY) 智通财经网·2025-08-14 22:28Core Viewpoint - The White House's actions to lower domestic drug prices are leading to increased drug prices in Europe, as exemplified by Eli Lilly's decision to raise its official drug prices in overseas markets [1][2]. Group 1: Company Actions - Eli Lilly announced an increase in its drug prices in overseas markets, stating that to lower U.S. drug prices, prices in other developed markets like Europe need to rise [1]. - The company raised the official price of its diabetes and obesity drug Mounjaro in the UK by 170% for the largest tablet specification, with lower doses seeing increases of 45% to 138% [2]. Group 2: Market Impact - Eli Lilly's price hikes in Europe may help offset potential profit losses from lowering prices in the U.S. and could also elevate the baseline for the proposed "most favored nation" pricing policy by the White House [2]. - Following the announcement, Eli Lilly's stock price rose by 3.62% [3].